Brief: Ryvu Therapeutics Got Full Approval To Conduct Phase I/II Study Of RVU120 In Patients With Relapsed/Refractory Metastatic Or Advanced Solid Tumors In Poland
28/05/2021 13:09
May 28 (Reuters) - Ryvu Therapeutics SA RVU.WA :
* RYVU THERAPEUTICS GOT FULL APPROVAL TO CONDUCT PHASE I/II
STUDY
OF RVU120 (SEL120) IN PATIENTS WITH RELAPSED/REFRACTORY
METASTATIC OR ADVANCED SOLID TUMORS IN POLAND
Source text for Eikon: ID:nPn5B3XPya
Further company coverage: RVU.WA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Signs Grant Agreement For Panacea-Novo Project With The National Center For Research And Development
Brief: Ryvu Therapeutics Q2 Net Loss 13.1 Million Zlotys
Brief: Ryvu Therapeutics "Dualis" Project Recommended For 22.2 Mln Zloty Subsidy
Brief: Ryvu Therapeutics Launches Early Clinical Development Services Business For Biotech And Pharma In Europe
Brief: Ryvu Therapeutics Says Panacea-Novo Project Recommended For Funding Of 106.7 Mln Zlotys